FDA approves pembrolizumab for treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation

This approval for treating the second most common form of skin cancer is based on data from phase II KEYNOTE-629 trial (n=105), in which pembrolizumab demonstrated an objective response rate of 34% including a complete response rate of 4% and a partial response rate of 31%.


Biospace Inc.